Emergent BioSolutions, Inc., finishes vaccinations in Phase IIb TB vaccine trial

Researchers have vaccinated the last of the 2,784 infants in a Phase IIb efficacy trial to evaluate MVA85A, a clinically advanced tuberculosis vaccine.

The trial, held in Worcester, South Africa, is connected with a joint venture between Emergent Biosolutions, Inc., Oxford University and the Oxford-Emergent Tuberculosis Consortium. The trial is being conducted by the University of Cape Town’s South African Tuberculosis Vaccine Initiative in partnership with Aeras and the Wellcome Trust.

“Emergent BioSolutions joined the fight against TB when it formed OETC with Oxford to further develop MVA85A,” Daniel J. Abdun-Nabi, chairman of the board, OETC and president and chief operating officer at Emergent BioSolutions, Inc., said. “We are pleased to complete the vaccination of our targeted 2,784 infants, which is the largest number of infants enrolled in any TB vaccine clinical trial. Our quest to fulfill Emergent’s corporate mission – to protect life – will come to fruition when we can bring this vaccine candidate to market and ultimately make an impact in patients’ lives.”

The trial was initiated in July 2009 and involves a two year follow up on the infants vaccinated to determine whether the vaccine candidate has conferred protection against TB.

“We are extremely proud of this achievement and are eager to see the study results, which are expected to be available as early as mid-2012,” Dr. Helen McShane, lead scientist and developer of MVA85A from the University of Oxford, said. “This milestone brings us a step closer to potentially having a new TB vaccine, from which millions of people around the world would benefit.”